Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation
Kidney and Blood Pressure Research · 2026
DOI: 10.1159/000552052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2026. Verfasst von Caixia Cui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Podocytes, Diabetic Nephropathies, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Podocyte injury is central to diabetic kidney disease (DKD). Metabolic reprogramming, particularly lactate accumulation, may drive podocyte injury via epigenetic mechanisms, yet this process remains poorly understood. This study aimed to clarify lactate’s role in podocyte injury and explore the protective effects of dapagliflozin.
Methods
We retrospectively analyzed plasma lactate levels in healthy individuals, patients with diabetes, and DKD patients and examined correlations with proteinuria. Subsequently, db/db mice and cultured podocytes were used to explore mechanisms of lactate-induced podocyte injury and potential protective effects of dapagliflozin in vivo and in vitro.
Results
Plasma lactate levels were analyzed in 66 healthy controls, 150 patients with diabetes, and 152 patients with DKD. Lactate concentrations were significantly higher in DKD patients compared with both diabetic patients and healthy controls. In DKD patients, lactate levels were positively correlated with serum creatinine and albuminuria. Logistic regression analysis identified hypertension, plasma lactate, white blood cell count, glycated hemoglobin, and serum creatinine as independent risk factors for DKD. Notably, dapagliflozin treatment significantly reduced plasma lactate levels in DKD patients. In diabetic mice and high-glucose-stimulated podocytes, marked lactate accumulation accompanied by increased histone H4 lysine 12 lactylation (H4K12la) was observed, indicating lactate-driven epigenetic regulation. In contrast, dapagliflozin treatment reduced lactate production and H4K12la levels, attenuated proteinuria, and ameliorated podocyte injury.
Conclusions
Lactate contributes to podocyte injury in DKD at least in part through promoting H4K12 lactylation. Dapagliflozin exerts renoprotective effects by attenuating this lactate-mediated epigenetic pathway, highlighting a potential therapeutic mechanism beyond glucose control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Liwan Central Hospital of Guangzhou, Guangzhou, China.
- Department of Nephrology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
- Department of Nephrology, Affiliated Hospital/Clinical Medical College of Chengdu University, Chengdu, China.
- Department of Nephrology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China, 13600097893@163.com.
- Department of Nephrology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China, 13925051974@163.com.
Zitieren
APA
Cui, C., Fu, N., Tao, S., Chen, J., Shang, Y., Peng, X., Zhao, Q., Kang, H., Wen, S., Peng, H., Xiao, J., Peng, Y., & Ke, G. (2026). Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation. Kidney and Blood Pressure Research. https://doi.org/10.1159/000552052
Vancouver
Cui C, Fu N, Tao S, Chen J, Shang Y, Peng X, et al. Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation. Kidney and Blood Pressure Research. 2026. doi:10.1159/000552052
BibTeX
@article{Cui2026,
author = {Cui, Caixia and Fu, Ningying and Tao, Shaoguo and Chen, Jiasi and Shang, Yuqi and Peng, Xuan and Zhao, Qian and Kang, Haiyan and Wen, Shanshan and Peng, Hongbo and Xiao, Jie and Peng, Yonghua and Ke, Guibao},
title = {Dapagliflozin May Attenuate Podocyte Injury in Diabetic Kidney Disease through Inhibition of Lactate-Mediated H4K12 Lactylation},
journal = {Kidney and Blood Pressure Research},
year = {2026},
doi = {10.1159/000552052}
}
EUVIMED